spironolactone has been researched along with Hirsutism in 160 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Hirsutism: A condition observed in WOMEN and CHILDREN when there is excess coarse body hair of an adult male distribution pattern, such as facial and chest areas. It is the result of elevated ANDROGENS from the OVARIES, the ADRENAL GLANDS, or exogenous sources. The concept does not include HYPERTRICHOSIS, which is an androgen-independent excessive hair growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our results revealed that metformin combined with spironolactone significantly reduced BMI and TT, but that it exerted no significant effects on hirsutism score, or on FSH or LH concentrations." | 9.41 | Metformin combined with spironolactone vs. metformin alone in polycystic ovary syndrome: a meta-analysis. ( Huang, L; Huang, S; Ren, W; Wu, J; Ye, Y; Zeng, H; Zhang, Y; Zhou, L, 2023) |
| "We aimed to compare a combined oral contraceptive (COC) plus the antiandrogen spironolactone with the insulin sensitizer metformin in women with polycystic ovary syndrome (PCOS)." | 9.24 | Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial. ( Alpañés, M; Álvarez-Blasco, F; Escobar-Morreale, HF; Fernández-Durán, E; Luque-Ramírez, M, 2017) |
| "The aim of this study was to evaluate and compare the effects of spironolactone and spironolactone plus metformin treatments on body mass index (BMI), hirsutism score, hormone levels, and insulin resistance in women with polycystic ovary syndrome (PCOS)." | 9.22 | Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome. ( Acmaz, B; Diri, H; Karaburgu, S; Karaca, Z; Kelestimur, F; Tanriverdi, F; Unluhizarci, K, 2016) |
| " It also indicates that the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism as compared to metformin alone." | 9.19 | In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. ( Belfiore, A; D'Orrico, B; Fava, A; Fruci, B; Guzzi, P; Malaguarnera, R; Mazza, A; Veltri, P, 2014) |
| "A total of 134 women with moderate and severe hirsutism were randomly assigned to three treatment regimens: Group I received 30 μg of ethinyl estradiol (EE)/3 mg of drospirenone (DRSP) plus 100 mg of cyproterone acetate (CPA) (n = 45); group II received 30 μg of EE/3 mg of DRSP plus 100 mg of spironolactone (n = 44); and group III received 35 μg of EE/2 mg of CPA plus 100 mg of CPA (n = 45), daily for 6 months." | 9.16 | Cyproterone acetate or drospirenone containing combined oral contraceptives plus spironolactone or cyproterone acetate for hirsutism: randomized comparison of three regimens. ( Gul, S; Kelekci, KH; Kelekci, S; Yengel, I; Yilmaz, B, 2012) |
| " Twenty-nine women with hirsutism as a consequence of PCOS or idiopathic hirsutism were randomly assigned to receive 250 mg/day flutamide alone or 100 mg/day spironolactone plus a combination tablet of 2 mg CPA/35 microg EE, for 6 months." | 9.13 | Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism: a randomised controlled study. ( Aral, Y; Bavbek, N; Culha, C; Demirbas, B; Güler, S; Karakurt, F; Sahin, I; Serter, R, 2008) |
| "To compare the clinical efficacy and safety of the combination of spironolactone (100 mg/day) plus finasteride (5 mg/day) and spironolactone (100 mg/day) alone in the treatment of hirsutism." | 9.11 | A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism. ( Bayram, F; Everest, H; Keleştimur, F; Sahin, Y; Unlühizarci, K, 2004) |
| "To compare the effectiveness of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism (IH)." | 9.11 | Comparison of the clinical efficacy of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism: a randomized controlled study. ( Inal, MM; Taner, CE; Yildirim, Y, 2005) |
| "To compare the effectiveness of cyproterone acetate, finasteride, and spironolactone in the treatment of idiopathic hirsutism." | 9.10 | Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism. ( Lumachi, F; Rondinone, R, 2003) |
| "The aim of the present study was to evaluate the effects of three different anti-androgenic drug-therapy regimens, Diane 35 (cyproterone acetate (CPA) [2 mg] and ethinyl estradiol [35 microg]) plus CPA, Diane 35 plus spironolactone, and spironolactone alone, in patients with hirsutism." | 9.10 | Comparison of the efficiency of anti-androgenic regimens consisting of spironolactone, Diane 35, and cyproterone acetate in hirsutism. ( Kirim, S; Sert, M; Tetiker, T, 2003) |
| "To compare objectively the efficacies of spironolactone (100 mg/day), flutamide (250 mg/day), and finasteride (5 mg/day) in the treatment of hirsutism, 40 hirsute women were randomly assigned to double blind treatments with 1 of these 3 drugs or placebo for 6 months." | 9.09 | Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. ( Caputo, M; Castello, R; Misciali, C; Moghetti, P; Muggeo, M; Negri, C; Perrone, F; Tosi, F; Tosti, A, 2000) |
| "To study the effectiveness and safety of spironolactone in the treatment of hirsute women and of the association of spironolactone plus dexamethasone in the treatment of hirsutism with glucocorticoid sensitive hyperandrogenism." | 9.09 | [Treatment of hirsutism with spironolactone and with spironolactone plus dexamethasone]. ( Aravena, L; Devoto, E; Ríos, R, 2000) |
| "To compare the efficacy of two antiandrogens, cyproterone acetate (CPA) and spironolactone, in the treatment of hirsutism." | 9.08 | Comparison of spironolactone-oral contraceptive versus cyproterone acetate-estrogen regimens in the treatment of hirsutism. ( Durmuşoğlu, F; Erenus, M; Gürbüz, O; Pekin, S; Yücelten, D, 1996) |
| "To compare the efficacy of finasteride and spironolactone in the treatment of idiopathic hirsutism." | 9.08 | Comparison of finasteride versus spironolactone in the treatment of idiopathic hirsutism. ( Durmuşoğlu, F; Erenus, M; Gürbüz, O; Yücelten, D, 1997) |
| "To compare the clinical efficacy and safety of Diane 35 (cyproterone acetate [2] mg and ethinyl estradiol [35 microg]) plus spironolactone [100 mg] combination and Diane 35 alone in the treatment of hirsutism." | 9.08 | Comparison of Diane 35 and Diane 35 plus spironolactone in the treatment of hirsutism. ( Keleştimur, F; Sahin, Y, 1998) |
| "To compare the efficacy of two antiandrogens, spironolactone and flutamide, in the treatment of hirsutism." | 9.07 | Comparison of the efficacy of spironolactone versus flutamide in the treatment of hirsutism. ( Demirçay, Z; Durmuşoğlu, F; Erenus, M; Gürbüz, O; Pekin, S, 1994) |
| "To compare the clinical efficacy and safety of the pure antiandrogen flutamide and the steroidal derivative spironolactone in the treatment of hirsutism in women." | 9.07 | Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. ( Cusan, L; Dupont, A; Gomez, JL; Labrie, F; Tremblay, RR, 1994) |
| "The effect of spironolactone on female hirsutism was studied in 18 patients." | 9.05 | Antiandrogenic properties of spironolactone. Clinical trial in the management of female hirsutism. ( Biffignandi, P; Manieri, C; Massucchetti, C; Messina, M; Molinatti, GM; Novi, RF, 1983) |
| "The objective was to investigate the effectiveness of spironolactone and/or in combination with steroids (oral contraceptive pill included) in reducing excess hair growth and/or acne in women." | 8.85 | Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. ( Brown, J; Farquhar, C; Jepson, RG; Lee, O; Toomath, R, 2009) |
| "The objective of this review was to investigate the effectiveness of spironolactone and/or in combination with steroids (oral contraceptive pill included) in reducing excess hair growth and/or acne in women." | 8.82 | Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. ( Farquhar, C; Jepson, R; Lee, O; Toomath, R, 2003) |
| "To evaluate the level of evidence for treatment of hirsutism associated with polycystic ovary syndrome (PCOS) with spironolactone." | 8.82 | Spironolactone for hirsutism in polycystic ovary syndrome. ( Christy, NA; Cross, LB; Franks, AS, 2005) |
| "The objective of this review was to investigate the effectiveness of spironolactone and/or in combination with steroids (oral contraceptive pill included) in reducing excess hair growth and/or acne in women." | 8.81 | Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. ( Farquhar, C; Jepson, R; Lee, O; Toomath, R, 2001) |
| "The objective of this review was to investigate the effectiveness of spironolactone and/or in combination with steroids (oral contraceptive pill included) in reducing excess hair growth and/or acne in women." | 8.80 | Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. ( Farquhar, C; Jepson, R; Lee, O; Toomath, R, 2000) |
| "Combined oral contraceptives (COC) and spironolactone are the first and second-line treatments of mild hirsutism, since the use of cyproterone acetate was restricted to the treatment of severe hirsutism by the French guidelines for hyperandrogenism published in May 2020." | 8.12 | [Impact of combined oral contraceptives and spironolactone on hirsutism and quality of life]. ( Begon, E; Bernard, V; Grouthier, V; Hocke, C; Lefoulon, N; Perrissin-Fabert, M, 2022) |
| "Metformin (an insulin sensitizer) and spironolactone (an antiandrogen) are both used for treatment of polycystic ovary syndrome." | 7.78 | Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis. ( Ammini, AC; Ganie, MA; Gupta, N; Kulshreshtha, B, 2012) |
| "To investigate the effects of spironolactone on serum lipids in women with hirsutism over a 3-month period." | 7.75 | Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism. ( Abbasi, M; Esteghamati, A; Hamidi, S; Nakhjavani, M; Nosratian-Jahromi, S; Pasalar, P, 2009) |
| "The antiandrogenic activity of spironolactone was used for treating hirsutism in 76 women, 29 of whom also had acne." | 7.68 | [Treatment of hirsutism with spironolactone and progestagen combination]. ( Dechaud, H; Elmidani, M; Garoscio-Cholet, M; Lejeune, H; Pugeat, M; Tourniaire, J, 1990) |
| "Spironolactone (Aldactone), 100 mg to 200 mg daily, has antiandrogenic effects that may enhance treatment of androgen-excess syndromes, particularly severe hirsutism." | 7.68 | Use of spironolactone in treatment of hirsutism. ( Cumming, DC, 1990) |
| "The research here reported concerns 9 hirsute women, four of them with PCO and five with idiopathic hirsutism, who underwent treatment with spironolactone." | 7.67 | Testosterone, 17 Ks, 17 beta E2 FSH-LH variations and hirsutism modifications during spironolactone therapy. ( Ambrosio, GB; De Salvia, D; Gangemi, M; Grandesso, R; Meneghetti, G; Nardelli, GB; Predebon, O; Spandri, P, 1984) |
| "Sixteen women with hirsutism used spironolactone, 100 mg daily without interruption, plus norethindrone (1 mg) and ethinyl estradiol (35 mg) for 21 of each 28 days." | 7.67 | Spironolactone and estrogen-progestin therapy for hirsutism. ( Board, JA; Rosenberg, SM; Smeltzer, JS, 1987) |
| "Spironolactone (100 mg) for 25 days in each menstrual cycle was assessed over 6 months for treatment of hirsutism in 35 patients." | 7.67 | Spironolactone in the treatment of hirsutism. ( Chapman, MG; Dewhurst, CJ; Dowsett, M; Hague, W; Jeffcoate, SL; Katz, M, 1986) |
| "The clinical efficacy of a combination of spironolactone and an oral contraceptive pill (Conova 30) was assessed in 23 patients presenting with hirsutism of whom 20 completed 6 months of treatment." | 7.67 | Spironolactone in combination with an oral contraceptive: an alternative treatment for hirsutism. ( Chapman, MG; Dewhurst, CJ; Dowsett, M; Jeffcoate, SL, 1985) |
| "The authors examined the effect of three months' treatment with spironolactone in 34 women with polycystic ovary syndrome." | 7.66 | Therapeutic effects of spironolactone in polycystic ovary syndrome. ( Kirschner, MA; Milewicz, A; Silber, D, 1983) |
| "Clinical and endocrine evaluations of 39 patients with hirsutism were performed to determine the effectiveness and site(s) of action of an antiandrogenic compound, spironolactone." | 7.66 | Treatment of hirsutism with spironolactone. ( Cumming, DC; Rebar, RW; Yang, JC; Yen, SS, 1982) |
| "Marked improvement in the severe hypertension (250/150 mmHg) and hirsutism of a patient suffering from polycystic ovary syndrome was quickly achieved by the use of spironolactone 200 mg per day." | 7.66 | Successful treatment of polycystic ovary syndrome with spironolactone or bromocriptine. ( Blum, I; Chovers, I; Kaufman, H; Marilus, R; Rusecki, Y, 1981) |
| "Two women with the polycystic ovary syndrome were treated with bromocriptine (15 to 20 mg/day) in combination with spironolactone (100 mg/day)." | 7.66 | Clinical evaluation of the effects of combined treatment with bromocriptine and spironolactone in two women with the polycystic ovary syndrome. ( Blum, I; Bruhis, S; Kaufman, H, 1981) |
| "After 8 months, hirsutism has improved in 24 (70." | 6.69 | [The treatment of hirsutism in adolescent girls with spironolactone]. ( Malinova, M, 1999) |
| "Treatment with spironolactone aims to attenuate androgen-mediated conditions including acne, hidradenitis suppurativa, female pattern hair loss and hirsutism." | 6.66 | Spironolactone in dermatology: uses in acne and beyond. ( Al-Niaimi, F; Ali, FR; Searle, TN, 2020) |
| "Hirsutism was classified according to Lorenzo (1970)." | 6.37 | Treatment of hirsutism with spironolactone. ( Tremblay, RR, 1986) |
| "Spironolactone (SP) is a potassium sparing diuretic with antiandrogenic properties." | 5.62 | Spironolactone hyaluronic acid enriched cerosomes (HAECs) for topical management of hirsutism: ( Albash, R; Darwish, KM; El-Dahmy, RM; Fahmy, AM; Hamed, MIA, 2021) |
| "Hirsutism is a dermatological condition that refers to the excessive growth of hair in androgen-sensitive areas in women." | 5.62 | Pharmaceutical and Pharmacological Evaluation of the Effect of Nano-Formulated Spironolactone and Progesterone on Inflammation and Hormonal Levels for Managing Hirsutism Experimentally Induced in Rats. ( Amer, RI; Fayez, AM; Mohamed, RA; Yassin, GE, 2021) |
| "Spironolactone is an economical potassium-sparing diuretic with an anti-androgenic effect and a good safety profile." | 5.56 | Spironolactone in Dermatology: Uses in Acne, Hidradenitis Suppurativa, Female Pattern Baldness, and Hirsutism. ( Morgado-Carrasco, D; Vargas-Mora, P, 2020) |
| "Spironolactone use as a treatment for hirsutism and other dermatological conditions among polycystic ovary syndrome (PCOS) and idiopathic hirsutism shows varied results." | 5.41 | Do Pleiotropic Effects of Spironolactone in Women with PCOS Make it More than an Anti-androgen? Evidence from a Systematic Review and Meta-analysis. ( Asrar, MM; Bashir, R; Ganie, MA; Shah, IA; Wani, IA, 2023) |
| "Our results revealed that metformin combined with spironolactone significantly reduced BMI and TT, but that it exerted no significant effects on hirsutism score, or on FSH or LH concentrations." | 5.41 | Metformin combined with spironolactone vs. metformin alone in polycystic ovary syndrome: a meta-analysis. ( Huang, L; Huang, S; Ren, W; Wu, J; Ye, Y; Zeng, H; Zhang, Y; Zhou, L, 2023) |
| "Spironolactone was used in 90 hirsute women because of its antiandrogenic effect." | 5.27 | Spironolactone in the treatment of hirsutism. ( Akyürek, C; Köksal, A; Pabuçcu, R, 1987) |
| "Spironolactone was equally effective in the treatment of idiopathic hirsutism and of the polycystic ovary syndrome." | 5.27 | Spironolactone in the treatment of idiopathic hirsutism and the polycystic ovary syndrome. ( Burke, CW; Evans, DJ, 1986) |
| "We aimed to compare a combined oral contraceptive (COC) plus the antiandrogen spironolactone with the insulin sensitizer metformin in women with polycystic ovary syndrome (PCOS)." | 5.24 | Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial. ( Alpañés, M; Álvarez-Blasco, F; Escobar-Morreale, HF; Fernández-Durán, E; Luque-Ramírez, M, 2017) |
| "While originally approved for the management of heart failure, hypertension, and edema, spironolactone is commonly used off label in the management of acne, hidradenitis, androgenetic alopecia, and hirsutism." | 5.22 | Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis. ( Barbieri, JS; Bommareddy, K; Hamade, H; Lopez-Olivo, MA; Tosh, T; Wehner, M, 2022) |
| "The aim of this study was to evaluate and compare the effects of spironolactone and spironolactone plus metformin treatments on body mass index (BMI), hirsutism score, hormone levels, and insulin resistance in women with polycystic ovary syndrome (PCOS)." | 5.22 | Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome. ( Acmaz, B; Diri, H; Karaburgu, S; Karaca, Z; Kelestimur, F; Tanriverdi, F; Unluhizarci, K, 2016) |
| " It also indicates that the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism as compared to metformin alone." | 5.19 | In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. ( Belfiore, A; D'Orrico, B; Fava, A; Fruci, B; Guzzi, P; Malaguarnera, R; Mazza, A; Veltri, P, 2014) |
| "A total of 134 women with moderate and severe hirsutism were randomly assigned to three treatment regimens: Group I received 30 μg of ethinyl estradiol (EE)/3 mg of drospirenone (DRSP) plus 100 mg of cyproterone acetate (CPA) (n = 45); group II received 30 μg of EE/3 mg of DRSP plus 100 mg of spironolactone (n = 44); and group III received 35 μg of EE/2 mg of CPA plus 100 mg of CPA (n = 45), daily for 6 months." | 5.16 | Cyproterone acetate or drospirenone containing combined oral contraceptives plus spironolactone or cyproterone acetate for hirsutism: randomized comparison of three regimens. ( Gul, S; Kelekci, KH; Kelekci, S; Yengel, I; Yilmaz, B, 2012) |
| " Twenty-nine women with hirsutism as a consequence of PCOS or idiopathic hirsutism were randomly assigned to receive 250 mg/day flutamide alone or 100 mg/day spironolactone plus a combination tablet of 2 mg CPA/35 microg EE, for 6 months." | 5.13 | Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism: a randomised controlled study. ( Aral, Y; Bavbek, N; Culha, C; Demirbas, B; Güler, S; Karakurt, F; Sahin, I; Serter, R, 2008) |
| "To compare the clinical efficacy and safety of the combination of spironolactone (100 mg/day) plus finasteride (5 mg/day) and spironolactone (100 mg/day) alone in the treatment of hirsutism." | 5.11 | A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism. ( Bayram, F; Everest, H; Keleştimur, F; Sahin, Y; Unlühizarci, K, 2004) |
| "To compare the effectiveness of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism (IH)." | 5.11 | Comparison of the clinical efficacy of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism: a randomized controlled study. ( Inal, MM; Taner, CE; Yildirim, Y, 2005) |
| "To compare the effectiveness of cyproterone acetate, finasteride, and spironolactone in the treatment of idiopathic hirsutism." | 5.10 | Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism. ( Lumachi, F; Rondinone, R, 2003) |
| "The aim of the present study was to evaluate the effects of three different anti-androgenic drug-therapy regimens, Diane 35 (cyproterone acetate (CPA) [2 mg] and ethinyl estradiol [35 microg]) plus CPA, Diane 35 plus spironolactone, and spironolactone alone, in patients with hirsutism." | 5.10 | Comparison of the efficiency of anti-androgenic regimens consisting of spironolactone, Diane 35, and cyproterone acetate in hirsutism. ( Kirim, S; Sert, M; Tetiker, T, 2003) |
| "Eighty-one hirsute women referred to a tertiary hirsutism clinic were assigned to one of three regimens: spironolactone 100 mg/day with an oral contraceptive, cyproterone acetate 50 mg/day on days 1 to 10 with an oral contraceptive, or flutamide 250 mg twice a day." | 5.09 | Recurrence rate of hirsutism after 3 different antiandrogen therapies. ( Durmuşoğlu, F; Erenus, M; Gürbüz, O; Yücelten, D, 1999) |
| "To compare objectively the efficacies of spironolactone (100 mg/day), flutamide (250 mg/day), and finasteride (5 mg/day) in the treatment of hirsutism, 40 hirsute women were randomly assigned to double blind treatments with 1 of these 3 drugs or placebo for 6 months." | 5.09 | Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. ( Caputo, M; Castello, R; Misciali, C; Moghetti, P; Muggeo, M; Negri, C; Perrone, F; Tosi, F; Tosti, A, 2000) |
| "To assess the androgen-suppressing effect of spironolactone, and the use of this drug as a single agent in the long-term therapy of hirsute patients with either polycystic ovary syndrome (PCOS) or idiopathic hirsutism (IH)." | 5.09 | Spironolactone as a single agent for long-term therapy of hirsute patients. ( Lhullier, F; Lisboa, KO; Mattiello, S; Spritzer, PM, 2000) |
| "This study explored the effect of the anti-androgen spironolactone on sex-hormone binding globulin (SHBG) and the distribution of circulating testosterone (T) into various free and bound fractions in seven women with hirsutism assessed before and then monthly for three months on a regimen of spironolactone, 100 mg bid as the sole therapeutic agent." | 5.08 | The effects of spironolactone on testosterone fractions and sex-hormone binding globulin binding capacity in hirsute women. ( Kirschner, MA; Lerário, AC; Luthold, WW; Marcondes, JA; Mendonça, BB; Minanni, SL; Nery, M; Wajchenberg, BL, 1995) |
| "To compare the efficacy of two antiandrogens, cyproterone acetate (CPA) and spironolactone, in the treatment of hirsutism." | 5.08 | Comparison of spironolactone-oral contraceptive versus cyproterone acetate-estrogen regimens in the treatment of hirsutism. ( Durmuşoğlu, F; Erenus, M; Gürbüz, O; Pekin, S; Yücelten, D, 1996) |
| "To compare the clinical efficacy and safety of Diane 35 (cyproterone acetate [2] mg and ethinyl estradiol [35 microg]) plus spironolactone [100 mg] combination and Diane 35 alone in the treatment of hirsutism." | 5.08 | Comparison of Diane 35 and Diane 35 plus spironolactone in the treatment of hirsutism. ( Keleştimur, F; Sahin, Y, 1998) |
| "To compare the efficacy of two antiandrogens, spironolactone and flutamide, in the treatment of hirsutism." | 5.07 | Comparison of the efficacy of spironolactone versus flutamide in the treatment of hirsutism. ( Demirçay, Z; Durmuşoğlu, F; Erenus, M; Gürbüz, O; Pekin, S, 1994) |
| "To compare the clinical efficacy and safety of the pure antiandrogen flutamide and the steroidal derivative spironolactone in the treatment of hirsutism in women." | 5.07 | Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. ( Cusan, L; Dupont, A; Gomez, JL; Labrie, F; Tremblay, RR, 1994) |
| "Because of its anti-androgenic activity spironolactone 50-200 mg daily is advocated widely for the management of female hirsutism but this practice lacks adequately controlled experimental support." | 5.06 | Lack of effect of spironolactone on hair shaft diameter in hirsute females. ( MacKie, R; McInnes, GT; McLellan, AR; Rentoul, J, 1989) |
| "The objective was to investigate the effectiveness of spironolactone and/or in combination with steroids (oral contraceptive pill included) in reducing excess hair growth and/or acne in women." | 4.85 | Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. ( Brown, J; Farquhar, C; Jepson, RG; Lee, O; Toomath, R, 2009) |
| " A significant reduction in hirsutism was found for flutamide, spironolactone, cyproterone acetate combined with an oral contraceptive, thiazolidinediones, oral contraceptive pills (OCPs), finasteride and metformin but not for placebo." | 4.84 | A systematic review of commonly used medical treatments for hirsutism in women. ( Conway, GS; Koulouri, O, 2008) |
| "The objective of this review was to investigate the effectiveness of spironolactone and/or in combination with steroids (oral contraceptive pill included) in reducing excess hair growth and/or acne in women." | 4.82 | Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. ( Farquhar, C; Jepson, R; Lee, O; Toomath, R, 2003) |
| "To evaluate the level of evidence for treatment of hirsutism associated with polycystic ovary syndrome (PCOS) with spironolactone." | 4.82 | Spironolactone for hirsutism in polycystic ovary syndrome. ( Christy, NA; Cross, LB; Franks, AS, 2005) |
| "The objective of this review was to investigate the effectiveness of spironolactone and/or in combination with steroids (oral contraceptive pill included) in reducing excess hair growth and/or acne in women." | 4.81 | Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. ( Farquhar, C; Jepson, R; Lee, O; Toomath, R, 2001) |
| "The objective of this review was to investigate the effectiveness of spironolactone and/or in combination with steroids (oral contraceptive pill included) in reducing excess hair growth and/or acne in women." | 4.80 | Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. ( Farquhar, C; Jepson, R; Lee, O; Toomath, R, 2000) |
| "Retrospective analysis of 63 women with hyperandrogenic skin symptoms due to polycystic ovary syndrome (PCOS), treated with spironolactone for at least 6 months as first-line treatment." | 4.31 | Long-Lasting Effects of Spironolactone after its Withdrawal in Patients with Hyperandrogenic Skin Disorders. ( Andrisani, A; Armanini, D; Barbot, M; Beggiao, F; Belloni Fortina, A; Bordin, L; Ceccato, F; Donà, G; Keiko Vedolin, C; Orlando, G; Ragazzi, E; Sabbadin, C; Scaroni, C, 2023) |
| "Metformin (an insulin sensitizer) and spironolactone (an antiandrogen) are both used for treatment of polycystic ovary syndrome." | 3.78 | Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis. ( Ammini, AC; Ganie, MA; Gupta, N; Kulshreshtha, B, 2012) |
| " 51 women completed a 6-month OCP trial (20 µg ethinyl estradiol + 75 µg gestodene, 21/28 days per cycle, plus 100 mg spironolactone in 32 women with moderate to severe hirsutism)." | 3.78 | Aromatase gene polymorphism does not influence clinical phenotype and response to oral contraceptive pills in polycystic ovary syndrome women. ( Maier, PS; Spritzer, PM, 2012) |
| "To investigate the effects of spironolactone on serum lipids in women with hirsutism over a 3-month period." | 3.75 | Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism. ( Abbasi, M; Esteghamati, A; Hamidi, S; Nakhjavani, M; Nosratian-Jahromi, S; Pasalar, P, 2009) |
| "Low-dose spironolactone improves hirsutism in a majority of hirsute women, irrespective of age, severity or duration of hirsutism, menstrual status, or serum hormone levels." | 3.68 | Predictors of clinical response in hirsute women treated with spironolactone. ( Crosby, PD; Rittmaster, RS, 1991) |
| "The antiandrogenic activity of spironolactone was used for treating hirsutism in 76 women, 29 of whom also had acne." | 3.68 | [Treatment of hirsutism with spironolactone and progestagen combination]. ( Dechaud, H; Elmidani, M; Garoscio-Cholet, M; Lejeune, H; Pugeat, M; Tourniaire, J, 1990) |
| "The research here reported concerns 9 hirsute women, four of them with PCO and five with idiopathic hirsutism, who underwent treatment with spironolactone." | 3.67 | Testosterone, 17 Ks, 17 beta E2 FSH-LH variations and hirsutism modifications during spironolactone therapy. ( Ambrosio, GB; De Salvia, D; Gangemi, M; Grandesso, R; Meneghetti, G; Nardelli, GB; Predebon, O; Spandri, P, 1984) |
| "Menstrual irregularity is a recognized side effect of spironolactone when used as a treatment for hirsutism in women." | 3.67 | Absence of progestational activity of oral spironolactone. ( Brumsted, JR; Gibson, M; Nakajima, ST; Riddick, DH, 1989) |
| "A survey of 54 patients taking spironolactone for hirsutes or acne showed that side-effects occurred in 91%; in 80% of patients, these were related to the anti-androgenic mechanism of the drug (menstrual disturbances, and breast enlargement and tenderness)." | 3.67 | Tolerance of spironolactone. ( Cunliffe, WJ; Hughes, BR, 1988) |
| "Sixteen women with hirsutism used spironolactone, 100 mg daily without interruption, plus norethindrone (1 mg) and ethinyl estradiol (35 mg) for 21 of each 28 days." | 3.67 | Spironolactone and estrogen-progestin therapy for hirsutism. ( Board, JA; Rosenberg, SM; Smeltzer, JS, 1987) |
| "Spironolactone and oral contraceptives have been used separately with some success in the treatment of hirsutism." | 3.67 | Prolonged suppression of hirsutism with combination therapy in an adolescent with insulin resistance and acanthosis nigricans. ( Moore, DC, 1987) |
| "Spironolactone (S) has been used successfully for the treatment of hirsutism." | 3.67 | The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. ( Brinton, D; Horton, R; Lobo, RA; Serafini, P; Shoupe, D, 1985) |
| "The clinical efficacy of a combination of spironolactone and an oral contraceptive pill (Conova 30) was assessed in 23 patients presenting with hirsutism of whom 20 completed 6 months of treatment." | 3.67 | Spironolactone in combination with an oral contraceptive: an alternative treatment for hirsutism. ( Chapman, MG; Dewhurst, CJ; Dowsett, M; Jeffcoate, SL, 1985) |
| "The authors examined the effect of three months' treatment with spironolactone in 34 women with polycystic ovary syndrome." | 3.66 | Therapeutic effects of spironolactone in polycystic ovary syndrome. ( Kirschner, MA; Milewicz, A; Silber, D, 1983) |
| "Clinical and endocrine evaluations of 39 patients with hirsutism were performed to determine the effectiveness and site(s) of action of an antiandrogenic compound, spironolactone." | 3.66 | Treatment of hirsutism with spironolactone. ( Cumming, DC; Rebar, RW; Yang, JC; Yen, SS, 1982) |
| "Marked improvement in the severe hypertension (250/150 mmHg) and hirsutism of a patient suffering from polycystic ovary syndrome was quickly achieved by the use of spironolactone 200 mg per day." | 3.66 | Successful treatment of polycystic ovary syndrome with spironolactone or bromocriptine. ( Blum, I; Chovers, I; Kaufman, H; Marilus, R; Rusecki, Y, 1981) |
| "Two women with the polycystic ovary syndrome were treated with bromocriptine (15 to 20 mg/day) in combination with spironolactone (100 mg/day)." | 3.66 | Clinical evaluation of the effects of combined treatment with bromocriptine and spironolactone in two women with the polycystic ovary syndrome. ( Blum, I; Bruhis, S; Kaufman, H, 1981) |
| "Minoxidil-induced sequential changes in plasma renin activity, urinary aldosterone and norepinephrine excretion were assessed in 11 patients with severe hypertension receiving propranolol or oxprenolol, chlorthalidone and spironolactone." | 3.66 | [Long-term minoxidil therapy: renin, aldosterone, noradrenaline and the need for beta blockers]. ( Brunner, HR; Ferguson, RK; Gavras, H; Jaeger, P; Jéquier, E; Turini, GA, 1978) |
| "Spironolactone is a drug, similar in structure to aldosterone and acts as an aldosterone receptor antagonist with an anti-androgenic effect." | 2.82 | Spironolactone in dermatology. ( Aguilar Medina, DA; Cazarín, J; Magaña, M, 2022) |
| "Polycystic ovary syndrome is the most common endocrinological problem associated with hirsutism." | 2.68 | Comparison of four different treatment regimes in hirsutism related to polycystic ovary syndrome. ( Gökmen, O; Gülekli, B; Işik, AZ; Senöz, S, 1996) |
| "Treatment with spironolactone aims to attenuate androgen-mediated conditions including acne, hidradenitis suppurativa, female pattern hair loss and hirsutism." | 2.66 | Spironolactone in dermatology: uses in acne and beyond. ( Al-Niaimi, F; Ali, FR; Searle, TN, 2020) |
| " Also it appears that individual differences in CPA bioavailability do not satisfactorily explain the lack of therapeutic response in about 30% of the cases." | 2.65 | Antiandrogens in the treatment of acne and hirsutism. ( Hammerstein, J; Moltz, L; Schwartz, U, 1983) |
| "Hirsutism is the excessive growth of terminal hair in a typical male pattern in a female." | 2.61 | Hirsutism in Women. ( Bain, J; Matheson, E, 2019) |
| "Flutamide was more effective than placebo in two studies (MD -7·60, 95% CI: -10·53 to -4·67 and MD -7·20, 95% CI: -10·15 to -4·25), as was spironolactone (MD -7·69, 95% CI: -10·12 to -5·26)." | 2.53 | Interventions for hirsutism excluding laser and photoepilation therapy alone: abridged Cochrane systematic review including GRADE assessments. ( Fedorowicz, Z; van Zuuren, EJ, 2016) |
| "Hirsutism is defined as excess hair growth in androgen-dependent areas of the body in women." | 2.46 | Hirsutism: Diagnosis and management. ( Brodell, LA; Mercurio, MG, 2010) |
| "In the treatment of hirsutism several options are now available, including pharmacologic regimens and cosmetic measures." | 2.46 | Medical Treatment of Hirsutism in Women ( Basso, SM; Lumachi, F, 2010) |
| "--Weight loss is an important part of the treatment of obese, hirsute women with PCOS." | 2.44 | [Hirsutism]. ( Pijl, H; van Zuuren, EJ, 2007) |
| "Although hirsutism and androgenetic alopecia are cosmetic problems, they can be psychologically devastating for women." | 2.40 | Antiandrogen treatment of polycystic ovary syndrome. ( Rittmaster, RS, 1999) |
| "Hirsutism was classified according to Lorenzo (1970)." | 2.37 | Treatment of hirsutism with spironolactone. ( Tremblay, RR, 1986) |
| " Such effects depend not only on increased androgen production by the ovary or adrenal gland but also on the bioavailability of androgen to peripheral tissues." | 2.37 | Anti-androgens in gynaecological practice. ( Franks, S; Reed, MJ, 1988) |
| "Acne is an off-label use of some COCs." | 1.72 | Female Pelvic Conditions: Polycystic Ovary Syndrome. ( Brady, PH; Gin, GT; Rosenblum, E; Wilkinson, LD, 2022) |
| "Spironolactone (SP) is a potassium sparing diuretic with antiandrogenic properties." | 1.62 | Spironolactone hyaluronic acid enriched cerosomes (HAECs) for topical management of hirsutism: ( Albash, R; Darwish, KM; El-Dahmy, RM; Fahmy, AM; Hamed, MIA, 2021) |
| "Hirsutism is a dermatological condition that refers to the excessive growth of hair in androgen-sensitive areas in women." | 1.62 | Pharmaceutical and Pharmacological Evaluation of the Effect of Nano-Formulated Spironolactone and Progesterone on Inflammation and Hormonal Levels for Managing Hirsutism Experimentally Induced in Rats. ( Amer, RI; Fayez, AM; Mohamed, RA; Yassin, GE, 2021) |
| "Spironolactone is an economical potassium-sparing diuretic with an anti-androgenic effect and a good safety profile." | 1.56 | Spironolactone in Dermatology: Uses in Acne, Hidradenitis Suppurativa, Female Pattern Baldness, and Hirsutism. ( Morgado-Carrasco, D; Vargas-Mora, P, 2020) |
| "Successful treatment of hirsutism with combination OC+SPL requires at least 6 months of therapy, with the proportion of satisfied patients continuing to increase with treatment duration." | 1.48 | Long-Term Response of Hirsutism and Other Hyperandrogenic Symptoms to Combination Therapy in Polycystic Ovary Syndrome. ( Azziz, R; Ezeh, U; Huang, A; Landay, M, 2018) |
| "Polycystic ovary syndrome is the underlying cause in the vast majority of patients with hirsutism; however, it should be kept in mind that it can only be diagnosed after exclusion of some other diseases such as non-classical congenital adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia and acromegaly." | 1.39 | Hirsutism - from diagnosis to use of antiandrogens. ( Karaca, Z; Kelestimur, F; Unluhizarci, K, 2013) |
| "Pneumomediastinum is an uncommon disease arising most frequently and remains largely underdiagnosed clinically, especially in young, healthy patients." | 1.38 | Pneumomediastinum after retching. ( Al, B; Genc, S; Murat, Ç; Sanli, M; Yildirim, C; Zengin, S, 2012) |
| "Hirsutism is the manifestation of hyperandrogenemia in PCOS." | 1.32 | The treatment of polycystic ovary syndrome. ( Ajossa, S; Guerriero, S; Melis, GB; Orrù, M; Paoletti, AM, 2004) |
| "Cyproterone acetate has been used in Europe for many years, but in the United States it has only been approved as an orphan drug to treat severe hirsutism." | 1.28 | Antiandrogens in the treatment of acne and hirsutism. ( Jurzyk, RS; Rose, LI; Spielvogel, RL, 1992) |
| " We investigated the dose-response relationship for suppression of dehydroepiandrosterone sulfate (DHEAS) with the use of dexamethasone." | 1.28 | Treatment of androgenic disorders with dexamethasone: dose-response relationship for suppression of dehydroepiandrosterone sulfate. ( Bedocs, NM; Bergfeld, W; Gidwani, GP; Gupta, MK; Parker, R; Redmond, GP; Skibinski, C, 1990) |
| " Cyproterone acetate allows differentiated treatment according to the various grades of hirsutism by modification of dosage and application." | 1.27 | [The concept of the causal therapy of hirsutism]. ( Schmidt, JB, 1986) |
| "Spironolactone was used in 90 hirsute women because of its antiandrogenic effect." | 1.27 | Spironolactone in the treatment of hirsutism. ( Akyürek, C; Köksal, A; Pabuçcu, R, 1987) |
| " In 11 women (68%), the dosage had to be decreased or the medication discontinued due to side-effects." | 1.27 | Side-effects of spironolactone therapy in the hirsute woman. ( Helfer, EL; Miller, JL; Rose, LI, 1988) |
| " One should, however, be aware that Diane contains only 2 mg cyproterone acetate (CPA) and a better effect would most probably have been obtained using a higher dosage of CPA." | 1.27 | A comparative study of Aldactone and Diane in the treatment of hirsutism. ( Djøseland, O; Lunde, O, 1987) |
| "Spironolactone was equally effective in the treatment of idiopathic hirsutism and of the polycystic ovary syndrome." | 1.27 | Spironolactone in the treatment of idiopathic hirsutism and the polycystic ovary syndrome. ( Burke, CW; Evans, DJ, 1986) |
| "The unbound fraction of plasma testosterone (T) can freely enter tissues, whereas the bioavailability of the albumin-bound T is controversial." | 1.27 | Bioavailability of albumin-bound testosterone. ( Bardin, CW; Cefalu, W; Manni, A; Nisula, BC; Pardridge, WM; Santen, RJ; Santner, SJ, 1985) |
| "Thirteen anovulatory oligomenorrheic, hyperandrogenic, and normoprolactinemic women were treated with spironolactone (aldactone) throughout six consecutive menstrual cycles in a dosage of 100 to 150 mg/day." | 1.26 | Induction of ovulation with spironolactone (Aldactone) in anovulatory oligomenorrheic and hyperandrogenic women. ( Diamant, YZ; Evron, S; Shapiro, G, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 66 (41.25) | 18.7374 |
| 1990's | 33 (20.63) | 18.2507 |
| 2000's | 28 (17.50) | 29.6817 |
| 2010's | 20 (12.50) | 24.3611 |
| 2020's | 13 (8.13) | 2.80 |
| Authors | Studies |
|---|---|
| Albash, R | 1 |
| Fahmy, AM | 1 |
| Hamed, MIA | 1 |
| Darwish, KM | 1 |
| El-Dahmy, RM | 1 |
| Aguilar Medina, DA | 1 |
| Cazarín, J | 1 |
| Magaña, M | 1 |
| Bommareddy, K | 1 |
| Hamade, H | 1 |
| Lopez-Olivo, MA | 1 |
| Wehner, M | 1 |
| Tosh, T | 1 |
| Barbieri, JS | 1 |
| Wilkinson, LD | 1 |
| Brady, PH | 1 |
| Gin, GT | 1 |
| Rosenblum, E | 1 |
| Sabbadin, C | 1 |
| Beggiao, F | 1 |
| Keiko Vedolin, C | 1 |
| Orlando, G | 1 |
| Ragazzi, E | 1 |
| Ceccato, F | 1 |
| Barbot, M | 1 |
| Bordin, L | 1 |
| Donà, G | 1 |
| Andrisani, A | 1 |
| Belloni Fortina, A | 1 |
| Scaroni, C | 1 |
| Armanini, D | 1 |
| Lefoulon, N | 1 |
| Begon, E | 1 |
| Perrissin-Fabert, M | 1 |
| Grouthier, V | 1 |
| Hocke, C | 1 |
| Bernard, V | 1 |
| Bashir, R | 1 |
| Asrar, MM | 1 |
| Shah, IA | 1 |
| Wani, IA | 1 |
| Ganie, MA | 2 |
| Zeng, H | 1 |
| Zhang, Y | 1 |
| Huang, S | 1 |
| Wu, J | 1 |
| Ren, W | 1 |
| Zhou, L | 1 |
| Huang, L | 1 |
| Ye, Y | 1 |
| Basu, P | 1 |
| Elman, SA | 1 |
| Abudu, B | 1 |
| Beckles, A | 1 |
| Salian, P | 1 |
| Yanes, DA | 1 |
| Porter, ML | 1 |
| Reynolds, RV | 2 |
| Vargas-Mora, P | 1 |
| Morgado-Carrasco, D | 1 |
| Heymann, WR | 1 |
| Searle, TN | 1 |
| Al-Niaimi, F | 1 |
| Ali, FR | 1 |
| Amer, RI | 1 |
| Yassin, GE | 1 |
| Mohamed, RA | 1 |
| Fayez, AM | 1 |
| Ibáñez, L | 1 |
| Del Río, L | 1 |
| Díaz, M | 1 |
| Sebastiani, G | 1 |
| Pozo, ÓJ | 1 |
| López-Bermejo, A | 1 |
| de Zegher, F | 1 |
| Alpañés, M | 1 |
| Álvarez-Blasco, F | 1 |
| Fernández-Durán, E | 1 |
| Luque-Ramírez, M | 1 |
| Escobar-Morreale, HF | 1 |
| Ezeh, U | 1 |
| Huang, A | 1 |
| Landay, M | 1 |
| Azziz, R | 1 |
| Azarchi, S | 1 |
| Bienenfeld, A | 1 |
| Lo Sicco, K | 1 |
| Marchbein, S | 1 |
| Shapiro, J | 1 |
| Nagler, AR | 1 |
| Matheson, E | 1 |
| Bain, J | 1 |
| Mazza, A | 1 |
| Fruci, B | 1 |
| Guzzi, P | 1 |
| D'Orrico, B | 1 |
| Malaguarnera, R | 1 |
| Veltri, P | 1 |
| Fava, A | 1 |
| Belfiore, A | 1 |
| Unluhizarci, K | 3 |
| Karaca, Z | 2 |
| Kelestimur, F | 7 |
| Buzney, E | 1 |
| Sheu, J | 1 |
| Buzney, C | 1 |
| van Zuuren, EJ | 3 |
| Fedorowicz, Z | 2 |
| Carter, B | 1 |
| Pandis, N | 1 |
| Diri, H | 1 |
| Karaburgu, S | 1 |
| Acmaz, B | 1 |
| Tanriverdi, F | 1 |
| Brown, J | 1 |
| Farquhar, C | 4 |
| Lee, O | 4 |
| Toomath, R | 4 |
| Jepson, RG | 1 |
| Koulouri, O | 2 |
| Conway, G | 1 |
| Nakhjavani, M | 1 |
| Hamidi, S | 1 |
| Esteghamati, A | 1 |
| Abbasi, M | 1 |
| Nosratian-Jahromi, S | 1 |
| Pasalar, P | 1 |
| Bachelot, A | 1 |
| Chabbert-Buffet, N | 1 |
| Salenave, S | 1 |
| Kerlan, V | 1 |
| Galand-Portier, MB | 1 |
| Artini, PG | 1 |
| Di Berardino, OM | 1 |
| Simi, G | 1 |
| Papini, F | 1 |
| Ruggiero, M | 1 |
| Monteleone, P | 1 |
| Cela, V | 1 |
| Brodell, LA | 1 |
| Mercurio, MG | 2 |
| Lumachi, F | 2 |
| Basso, SM | 1 |
| Kelekci, KH | 1 |
| Kelekci, S | 1 |
| Yengel, I | 1 |
| Gul, S | 1 |
| Yilmaz, B | 1 |
| Maier, PS | 2 |
| Mattiello, SS | 1 |
| Lages, L | 1 |
| Spritzer, PM | 3 |
| Kulshreshtha, B | 1 |
| Gupta, N | 1 |
| Ammini, AC | 1 |
| Al, B | 1 |
| Yildirim, C | 1 |
| Zengin, S | 1 |
| Murat, Ç | 1 |
| Genc, S | 1 |
| Sanli, M | 1 |
| Amesse, LS | 1 |
| Ding, X | 1 |
| Pfaff-Amesse, T | 1 |
| Unlühizarci K, K | 1 |
| Everest, H | 2 |
| Bayram, F | 2 |
| Rondinone, R | 1 |
| Sert, M | 1 |
| Tetiker, T | 1 |
| Kirim, S | 1 |
| Jepson, R | 3 |
| Ajossa, S | 1 |
| Guerriero, S | 1 |
| Paoletti, AM | 1 |
| Orrù, M | 1 |
| Melis, GB | 1 |
| Sahin, Y | 3 |
| Guzelmeric, K | 1 |
| Seker, N | 1 |
| Unal, O | 1 |
| Turan, C | 1 |
| Al-Inany, H | 1 |
| Christy, NA | 1 |
| Franks, AS | 1 |
| Cross, LB | 1 |
| Inal, MM | 1 |
| Yildirim, Y | 1 |
| Taner, CE | 1 |
| Conway, GS | 1 |
| Pijl, H | 1 |
| Yildiz, BO | 1 |
| Karakurt, F | 1 |
| Sahin, I | 1 |
| Güler, S | 1 |
| Demirbas, B | 1 |
| Culha, C | 1 |
| Serter, R | 1 |
| Aral, Y | 1 |
| Bavbek, N | 1 |
| Biffignandi, P | 3 |
| Massucchetti, C | 2 |
| Molinatti, GM | 5 |
| Zaun, H | 1 |
| Braithwaite, SS | 1 |
| Jabamoni, R | 1 |
| De Pedrini, P | 2 |
| Suraci, C | 2 |
| Costa, C | 2 |
| Hammerstein, J | 1 |
| Moltz, L | 1 |
| Schwartz, U | 1 |
| Shoupe, D | 2 |
| Lobo, RA | 7 |
| Belaube, P | 1 |
| Devaux, J | 1 |
| Gamby, T | 1 |
| Garcin, G | 1 |
| Privat, Y | 1 |
| Messina, M | 1 |
| Manieri, C | 1 |
| Novi, RF | 1 |
| Spandri, P | 1 |
| Gangemi, M | 1 |
| Nardelli, GB | 1 |
| Meneghetti, G | 1 |
| Grandesso, R | 1 |
| De Salvia, D | 1 |
| Ambrosio, GB | 1 |
| Predebon, O | 1 |
| Abramovici, Y | 1 |
| Guillet, F | 1 |
| Matte, R | 1 |
| Chaieb, L | 1 |
| Belanger, R | 1 |
| Ylöstalo, P | 2 |
| Hána, V | 1 |
| Marek, J | 1 |
| Gregorová, I | 1 |
| Evron, S | 2 |
| Shapiro, G | 2 |
| Diamant, YZ | 1 |
| Milewicz, A | 1 |
| Silber, D | 1 |
| Kirschner, MA | 3 |
| Gamborg Nielsen, P | 1 |
| Mitra, K | 1 |
| Chaudhuri, N | 1 |
| Kundu, D | 1 |
| Mondal, S | 1 |
| Ghose, D | 1 |
| Baranowska, B | 1 |
| Stopińska-Głuszak, U | 1 |
| Niewiadomska, A | 1 |
| Zgliczyński, S | 1 |
| Cumming, DC | 2 |
| Yang, JC | 1 |
| Rebar, RW | 1 |
| Yen, SS | 1 |
| Blum, I | 2 |
| Kaufman, H | 2 |
| Marilus, R | 1 |
| Rusecki, Y | 1 |
| Chovers, I | 1 |
| Bruhis, S | 1 |
| Ross, HD | 1 |
| Marcondes, JA | 1 |
| Minanni, SL | 1 |
| Luthold, WW | 1 |
| Lerário, AC | 1 |
| Nery, M | 1 |
| Mendonça, BB | 1 |
| Wajchenberg, BL | 1 |
| Wong, IL | 1 |
| Morris, RS | 1 |
| Chang, L | 1 |
| Spahn, MA | 1 |
| Stanczyk, FZ | 1 |
| Erenus, M | 5 |
| Vĕtr, M | 2 |
| Sobek, A | 1 |
| McMullen, GR | 1 |
| Van Herle, AJ | 1 |
| Gürbüz, O | 4 |
| Durmuşoğlu, F | 4 |
| Demirçay, Z | 1 |
| Pekin, S | 2 |
| Cusan, L | 1 |
| Dupont, A | 1 |
| Gomez, JL | 1 |
| Tremblay, RR | 3 |
| Labrie, F | 1 |
| Yücelten, D | 3 |
| Gökmen, O | 1 |
| Senöz, S | 1 |
| Gülekli, B | 1 |
| Işik, AZ | 1 |
| Zemtsov, A | 1 |
| Wilson, L | 1 |
| Carmina, E | 2 |
| Young, R | 1 |
| Sinclair, R | 1 |
| Moghetti, P | 3 |
| Castello, R | 3 |
| Zamberlan, N | 1 |
| Rossini, M | 1 |
| Gatti, D | 1 |
| Negri, C | 3 |
| Tosi, F | 3 |
| Muggeo, M | 3 |
| Adami, S | 1 |
| Rittmaster, RS | 2 |
| Dorizzi, R | 1 |
| Fortunato, A | 1 |
| Spiazzi, GG | 1 |
| Tosti, A | 1 |
| Misciali, C | 1 |
| Perrone, F | 1 |
| Caputo, M | 1 |
| Malinova, M | 1 |
| Lisboa, KO | 1 |
| Mattiello, S | 1 |
| Lhullier, F | 1 |
| Gregoriou, O | 1 |
| Bakas, P | 1 |
| Konidaris, S | 1 |
| Papadias, K | 1 |
| Mathiopoulos, D | 1 |
| Creatsas, G | 1 |
| Devoto, E | 1 |
| Aravena, L | 1 |
| Ríos, R | 1 |
| Boisselle, A | 1 |
| Jaeger, P | 1 |
| Brunner, HR | 1 |
| Turini, GA | 1 |
| Jéquier, E | 1 |
| Ferguson, RK | 1 |
| Gavras, H | 1 |
| Ober, KP | 1 |
| Hennessy, JF | 1 |
| Cunliffe, WJ | 3 |
| Jurzyk, RS | 1 |
| Spielvogel, RL | 1 |
| Rose, LI | 3 |
| Bassaw, B | 1 |
| Maharaj, R | 1 |
| Ali, A | 1 |
| Roopnarinesingh, S | 1 |
| Shaw, JC | 1 |
| O'Brien, RC | 1 |
| Cooper, ME | 1 |
| Murray, RM | 1 |
| Seeman, E | 1 |
| Thomas, AK | 2 |
| Jerums, G | 2 |
| Crosby, PD | 1 |
| Wild, RA | 1 |
| Demers, LM | 1 |
| Applebaum-Bowden, D | 1 |
| Lenker, R | 1 |
| Derksen, J | 1 |
| Krulder, JW | 1 |
| Redmond, GP | 1 |
| Gidwani, GP | 1 |
| Gupta, MK | 1 |
| Bedocs, NM | 1 |
| Parker, R | 1 |
| Skibinski, C | 1 |
| Bergfeld, W | 1 |
| Pugeat, M | 1 |
| Elmidani, M | 1 |
| Dechaud, H | 1 |
| Garoscio-Cholet, M | 1 |
| Lejeune, H | 1 |
| Tourniaire, J | 1 |
| Sciarra, F | 1 |
| Toscano, V | 1 |
| Concolino, G | 1 |
| Di Silverio, F | 1 |
| Adashi, EY | 1 |
| McKenna, KM | 1 |
| Pepperell, RJ | 1 |
| Evans, J | 1 |
| Prezelj, J | 1 |
| Kocijancic, A | 1 |
| Andolsek, L | 1 |
| McLellan, AR | 1 |
| Rentoul, J | 1 |
| MacKie, R | 1 |
| McInnes, GT | 1 |
| Barth, JH | 1 |
| Cherry, CA | 1 |
| Wojnarowska, F | 1 |
| Dawber, RP | 1 |
| Nakajima, ST | 1 |
| Brumsted, JR | 1 |
| Riddick, DH | 1 |
| Gibson, M | 2 |
| Slobodniuk, R | 1 |
| Taft, J | 1 |
| Cooper, M | 1 |
| Montalto, J | 1 |
| Komarov, EK | 1 |
| Svechnikova, FA | 1 |
| Khrustaleva, GF | 1 |
| Schmidt, JB | 1 |
| Young, RL | 1 |
| Goldzieher, JW | 1 |
| Elkind-Hirsch, K | 1 |
| Hughes, BR | 1 |
| Reed, MJ | 1 |
| Franks, S | 1 |
| Callan, AW | 1 |
| Serafini, P | 2 |
| Köksal, A | 1 |
| Pabuçcu, R | 1 |
| Akyürek, C | 1 |
| Burke, BM | 1 |
| Kvedar, JC | 1 |
| Krusinski, PA | 1 |
| Pittaway, DE | 1 |
| Maxson, WS | 1 |
| Wentz, AC | 1 |
| Anttila, L | 1 |
| Ruutiainen, K | 1 |
| Erkkola, R | 1 |
| Helfer, EL | 2 |
| Miller, JL | 1 |
| Board, JA | 1 |
| Rosenberg, SM | 1 |
| Smeltzer, JS | 1 |
| Siegberg, R | 1 |
| Laatikainen, T | 1 |
| Pelkonen, R | 1 |
| Stenman, UH | 1 |
| Lunde, O | 1 |
| Djøseland, O | 1 |
| Samojlik, E | 1 |
| Szmal, E | 1 |
| Moore, DC | 1 |
| Chapman, MG | 2 |
| Katz, M | 1 |
| Dowsett, M | 2 |
| Hague, W | 1 |
| Jeffcoate, SL | 2 |
| Dewhurst, CJ | 2 |
| Evans, DJ | 1 |
| Burke, CW | 1 |
| Buckshee, K | 1 |
| Ahuja, MM | 1 |
| Morris, DV | 1 |
| Guillebaud, J | 1 |
| Brinton, D | 1 |
| Horton, R | 1 |
| Givens, JR | 1 |
| Serafini, PC | 1 |
| Catalino, J | 1 |
| Manni, A | 1 |
| Pardridge, WM | 1 |
| Cefalu, W | 1 |
| Nisula, BC | 1 |
| Bardin, CW | 1 |
| Santner, SJ | 1 |
| Santen, RJ | 1 |
| Dorrington-Ward, P | 1 |
| McCartney, AC | 1 |
| Holland, S | 1 |
| Scully, J | 1 |
| Carter, G | 1 |
| Alaghband-Zadeh, J | 1 |
| Wise, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Metformin Versus Metfotmin Plus Low-dose Spironolactone in the Treatment of Overweight/Obese Patients With Polycystic Ovary Syndrome: a Randomized Study[NCT01526616] | 56 participants (Actual) | Interventional | 2010-05-31 | Completed | |||
| Gender Affirmative Treatment of Hypertrichosis With Intense Pulsed Light - Effect on Hair Reduction and Quality of Life[NCT05775328] | 39 participants (Anticipated) | Observational | 2023-12-01 | Not yet recruiting | |||
| 17-hydroxysteroid Dehydrogenase Type 5 Gene Polymorphism (71A/G HSD17B5 SNP) and Effects of Oral Contraceptive Pill on Hirsutism, Androgens and Metabolic Profile in Non-obese PCOS Women: a Pilot Study[NCT01372293] | 49 participants (Actual) | Interventional | 2005-01-31 | Completed | |||
| Clinical Metabolic and Endocrine Parameters in Response to Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome: A Phase 4 Randomized, Double- Blind and Placebo Control Trial[NCT00679679] | Phase 4 | 30 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
36 reviews available for spironolactone and Hirsutism
| Article | Year |
|---|---|
Spironolactone in dermatology.
Topics: Acne Vulgaris; Dermatology; Female; Hidradenitis Suppurativa; Hirsutism; Humans; Spironolactone | 2022 |
Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis.
Topics: Acne Vulgaris; Aged; Breast Neoplasms; Female; Hirsutism; Humans; Male; Middle Aged; Prostatic Neopl | 2022 |
Do Pleiotropic Effects of Spironolactone in Women with PCOS Make it More than an Anti-androgen? Evidence from a Systematic Review and Meta-analysis.
Topics: Androgen Antagonists; Female; Finasteride; Hirsutism; Humans; Polycystic Ovary Syndrome; Spironolact | 2023 |
Metformin combined with spironolactone vs. metformin alone in polycystic ovary syndrome: a meta-analysis.
Topics: Drug-Related Side Effects and Adverse Reactions; Female; Follicle Stimulating Hormone, Human; Hirsut | 2023 |
Spironolactone in dermatology: uses in acne and beyond.
Topics: Acne Vulgaris; Adult; Alopecia; Dermatology; Drug Monitoring; Female; Hidradenitis Suppurativa; Hirs | 2020 |
Androgens in women: Hormone-modulating therapies for skin disease.
Topics: 5-alpha Reductase Inhibitors; Acne Vulgaris; Adrenal Hyperplasia, Congenital; Alopecia; Androgen Ant | 2019 |
Hirsutism in Women.
Topics: Adrenal Hyperplasia, Congenital; Androgen Antagonists; Antineoplastic Agents, Hormonal; Contraceptiv | 2019 |
Polycystic ovary syndrome: a review for dermatologists: Part II. Treatment.
Topics: 5-alpha Reductase Inhibitors; Acne Vulgaris; Alopecia; Androgen Antagonists; Contraceptives, Oral, C | 2014 |
Interventions for hirsutism (excluding laser and photoepilation therapy alone).
Topics: 5-alpha Reductase Inhibitors; Adult; Androgen Antagonists; Body Mass Index; Contraceptive Agents, Fe | 2015 |
Interventions for hirsutism excluding laser and photoepilation therapy alone: abridged Cochrane systematic review including GRADE assessments.
Topics: 5-alpha Reductase Inhibitors; Adolescent; Androgen Antagonists; Body Mass Index; Contraceptives, Ora | 2016 |
Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne.
Topics: Acne Vulgaris; Androgen Antagonists; Drug Therapy, Combination; Female; Hirsutism; Humans; Randomize | 2009 |
Anti-androgen treatments.
Topics: Androgen Antagonists; Cyproterone Acetate; Estrogens; Female; Finasteride; Flutamide; Gonadotropin-R | 2010 |
Best methods for identification and treatment of PCOS.
Topics: Androgens; Aromatase Inhibitors; Clomiphene; Contraceptives, Oral, Hormonal; Diagnosis, Differential | 2010 |
Hirsutism: Diagnosis and management.
Topics: 5-alpha Reductase Inhibitors; Adrenal Hyperplasia, Congenital; Causality; Contraceptives, Oral; Diag | 2010 |
Medical Treatment of Hirsutism in Women
Topics: Androgen Antagonists; Contraceptives, Oral; Cyproterone Acetate; Estrogens; Female; Hair Removal; Hi | 2010 |
Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne.
Topics: Acne Vulgaris; Drug Therapy, Combination; Female; Glucocorticoids; Hirsutism; Humans; Male; Mineralo | 2003 |
Medical treatment regimens of hirsutism.
Topics: Androgen Antagonists; Cyproterone Acetate; Drug Combinations; Enzyme Inhibitors; Ethinyl Estradiol; | 2004 |
Polycystic ovary syndrome.
Topics: Androgen Antagonists; Cyproterone Acetate; Drug Therapy, Combination; Ethinyl Estradiol; Female; Fin | 2004 |
Spironolactone for hirsutism in polycystic ovary syndrome.
Topics: Female; Hirsutism; Humans; Mineralocorticoid Receptor Antagonists; Polycystic Ovary Syndrome; Spiron | 2005 |
A systematic review of commonly used medical treatments for hirsutism in women.
Topics: Androgen Antagonists; Contraceptives, Oral, Hormonal; Cyproterone Acetate; Drug Therapy, Combination | 2008 |
[Hirsutism].
Topics: Androgen Antagonists; Androgens; Contraceptives, Oral; Cyproterone Acetate; Female; Hirsutism; Human | 2007 |
Female hirsutism: pathophysiological considerations and therapeutic implications.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Adrenal Glands; Adrenocorticotropic Hormone; Androgen Antagon | 1984 |
Hirsutism.
Topics: 17-Ketosteroids; Adrenal Gland Neoplasms; Adrenal Hyperplasia, Congenital; Androgen Antagonists; And | 1983 |
Hirsutism and the effectiveness of spironolactone in its management.
Topics: Androgen Antagonists; Clinical Trials as Topic; Hirsutism; Humans; Spironolactone | 1993 |
Hirsutes. II: Treatment.
Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Androgen Receptor Antagonists; Contraceptives, O | 1998 |
Antiandrogen treatment of polycystic ovary syndrome.
Topics: Alopecia; Androgen Antagonists; Androgens; Cyproterone Acetate; Female; Finasteride; Flutamide; Hirs | 1999 |
Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne.
Topics: Acne Vulgaris; Drug Therapy, Combination; Female; Glucocorticoids; Hirsutism; Humans; Male; Mineralo | 2000 |
Hirsutism: diagnosis and management.
Topics: Adrenal Hyperplasia, Congenital; Androgens; Contraceptives, Oral; Eflornithine; Enzyme Inhibitors; F | 2001 |
Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne.
Topics: Acne Vulgaris; Drug Therapy, Combination; Female; Glucocorticoids; Hirsutism; Humans; Male; Mineralo | 2001 |
Spironolactone in dermatologic therapy.
Topics: Acne Vulgaris; Animals; Endocrine Glands; Hirsutism; Humans; Skin Diseases; Spironolactone | 1991 |
Potential utility of gonadotropin-releasing hormone agonists in the management of ovarian hyperandrogenism.
Topics: Androgen Antagonists; Androgens; Biomechanical Phenomena; Contraceptives, Oral; Drug Therapy, Combin | 1990 |
Treatment of hirsutism with spironolactone.
Topics: 17-alpha-Hydroxyprogesterone; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Female; Hirsut | 1986 |
Anti-androgens in gynaecological practice.
Topics: Acne Vulgaris; Androgen Antagonists; Androgens; Cyproterone; Female; Hirsutism; Humans; Spironolacto | 1988 |
Spironolactone therapy in hirsutism and acne.
Topics: Acne Vulgaris; Androgens; Drug Administration Schedule; Female; Hirsutism; Humans; Recurrence; Spiro | 1988 |
Hirsutism: evaluation and treatment.
Topics: Contraceptives, Oral; Dehydroepiandrosterone; Dexamethasone; Dihydrotestosterone; Female; Hair Remov | 1985 |
Hirsutism.
Topics: Adrenal Glands; Adrenal Hyperplasia, Congenital; Adrenocortical Hyperfunction; Androgens; Cimetidine | 1985 |
40 trials available for spironolactone and Hirsutism
| Article | Year |
|---|---|
Normalizing Ovulation Rate by Preferential Reduction of Hepato-Visceral Fat in Adolescent Girls With Polycystic Ovary Syndrome.
Topics: Adolescent; Body Mass Index; Contraceptives, Oral, Combined; Drug Combinations; Ethinyl Estradiol; F | 2017 |
Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial.
Topics: Adult; Contraceptives, Oral, Combined; Drug Administration Schedule; Female; Hirsutism; Humans; Hypo | 2017 |
In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone.
Topics: Adult; Androstenedione; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Female; Hirsutism; | 2014 |
Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome.
Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; Dehydroepiandrosterone Sulfate; Drug Therapy, Com | 2016 |
Cyproterone acetate or drospirenone containing combined oral contraceptives plus spironolactone or cyproterone acetate for hirsutism: randomized comparison of three regimens.
Topics: Adolescent; Adult; Androgen Antagonists; Androstenes; Contraceptives, Oral, Combined; Cyproterone Ac | 2012 |
17-Hydroxysteroid dehydrogenase type 5 gene polymorphism (-71A/G HSD17B5 SNP) and treatment with oral contraceptive pills in PCOS women without metabolic comorbidities.
Topics: 3-Hydroxysteroid Dehydrogenases; Adolescent; Adult; Aldo-Keto Reductase Family 1 Member C3; Brazil; | 2012 |
Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Androgen Antagonists; Androstenedione; Cyproterone | 2003 |
Comparison of the efficiency of anti-androgenic regimens consisting of spironolactone, Diane 35, and cyproterone acetate in hirsutism.
Topics: Adolescent; Adult; Androgen Antagonists; Cyproterone Acetate; Drug Combinations; Ethinyl Estradiol; | 2003 |
A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism.
Topics: Adult; Dehydroepiandrosterone Sulfate; Drug Therapy, Combination; Enzyme Inhibitors; Female; Finaste | 2004 |
Comparison of the clinical efficacy of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism: a randomized controlled study.
Topics: Adult; Androgen Antagonists; Cyproterone Acetate; Diuretics; Drug Combinations; Drug Therapy, Combin | 2005 |
Comparison of the clinical efficacy of flutamide and spironolactone plus ethinyloestradiol/cyproterone acetate in the treatment of hirsutism: a randomised controlled study.
Topics: Adult; Androgen Antagonists; Cyproterone Acetate; Drug Combinations; Drug Therapy, Combination; Ethi | 2008 |
Antiandrogens in the treatment of acne and hirsutism.
Topics: Acne Vulgaris; Androgen Antagonists; Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Dru | 1983 |
Antiandrogenic properties of spironolactone. Clinical trial in the management of female hirsutism.
Topics: Adult; Androgen Antagonists; Female; Follicle Stimulating Hormone; Hirsutism; Humans; Luteinizing Ho | 1983 |
The effects of spironolactone on testosterone fractions and sex-hormone binding globulin binding capacity in hirsute women.
Topics: Adolescent; Adult; Body Weight; Dehydroepiandrosterone; Estradiol; Female; Hirsutism; Hormone Antago | 1995 |
A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women.
Topics: Adolescent; Adult; Female; Finasteride; Hair; Hirsutism; Hormones; Humans; Prospective Studies; Spir | 1995 |
Efficacy of flutamide versus spironolactone.
Topics: Contraceptives, Oral; Female; Flutamide; Hirsutism; Humans; Incidence; Menstruation Disturbances; Sp | 1995 |
Low dose spironolactone in the treatment of female hyperandrogenemia and hirsutism.
Topics: Adolescent; Adult; Female; Hirsutism; Humans; Hyperandrogenism; Infant, Newborn; Luteinizing Hormone | 1993 |
Comparison of the efficacy of spironolactone versus flutamide in the treatment of hirsutism.
Topics: Adolescent; Adult; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Female; Flutamide; Follic | 1994 |
Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial.
Topics: Adult; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Estradiol; Female; Flutamide; Follicl | 1994 |
Comparison of spironolactone-oral contraceptive versus cyproterone acetate-estrogen regimens in the treatment of hirsutism.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Contraceptives, Oral, Synthetic; Cyproterone Acetat | 1996 |
Comparison of four different treatment regimes in hirsutism related to polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgen Antagonists; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Contrac | 1996 |
Comparison of finasteride versus spironolactone in the treatment of idiopathic hirsutism.
Topics: Adult; Drug Administration Schedule; Enzyme Inhibitors; Female; Finasteride; Gonadal Steroid Hormone | 1997 |
Comparison of Diane 35 and Diane 35 plus spironolactone in the treatment of hirsutism.
Topics: Adolescent; Adult; Cyproterone Acetate; Drug Combinations; Estradiol Congeners; Ethinyl Estradiol; F | 1998 |
The addition of dexamethasone to antiandrogen therapy for hirsutism prolongs the duration of remission.
Topics: Adult; Androgen Antagonists; Cohort Studies; Dexamethasone; Drug Combinations; Female; Follow-Up Stu | 1998 |
Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist.
Topics: Adult; Bone and Bones; Bone Density; Bone Resorption; Female; Flutamide; Hirsutism; Humans; Polycyst | 1999 |
Recurrence rate of hirsutism after 3 different antiandrogen therapies.
Topics: Androgen Antagonists; Contraceptives, Oral; Cyproterone; Female; Flutamide; Hirsutism; Humans; Lutei | 1999 |
Antiandrogen drugs lower serum prostate-specific antigen (PSA) levels in hirsute subjects: evidence that serum PSA is a marker of androgen action in women.
Topics: Adult; Androgen Antagonists; Androgens; Androstane-3,17-diol; Biomarkers; Double-Blind Method; Enzym | 2000 |
Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial.
Topics: Adult; Androgen Antagonists; Double-Blind Method; Female; Finasteride; Flutamide; Hair; Hirsutism; H | 2000 |
[The treatment of hirsutism in adolescent girls with spironolactone].
Topics: Adolescent; Androgen Antagonists; Female; Hirsutism; Humans; Menstrual Cycle; Spironolactone; Time F | 1999 |
Spironolactone as a single agent for long-term therapy of hirsute patients.
Topics: Adolescent; Adult; Androgen Antagonists; Androstenedione; Cyproterone Acetate; Drug Therapy, Combina | 2000 |
The effect of combined oral contraception with or without spironolactone on bone mineral density of hyperandrogenic women.
Topics: Adult; Alkaline Phosphatase; Bone Density; Calcium; Contraceptives, Oral, Combined; Desogestrel; Dru | 2000 |
[Treatment of hirsutism with spironolactone and with spironolactone plus dexamethasone].
Topics: Adolescent; Adult; Dexamethasone; Drug Therapy, Combination; Female; Follow-Up Studies; Glucocortico | 2000 |
Comparison of sequential cyproterone acetate/estrogen versus spironolactone/oral contraceptive in the treatment of hirsutism.
Topics: Adult; Androgen Antagonists; Androgens; Contraceptives, Oral; Cyproterone; Cyproterone Acetate; Drug | 1991 |
Hirsutism: metabolic effects of two commonly used oral contraceptives and spironolactone.
Topics: Analysis of Variance; Androstane-3,17-diol; Blood Pressure; Body Weight; Cholesterol, HDL; Ethinyl E | 1991 |
Antiandrogens: clinical applications.
Topics: Acne Vulgaris; Adult; Androgen Antagonists; Cyproterone; Cyproterone Acetate; Dermatitis, Seborrheic | 1990 |
Dexamethasone and spironolactone in the treatment of non-tumorous hyperandrogenism.
Topics: Adolescent; Adult; Androgens; Dexamethasone; Drug Therapy, Combination; Estrogens; Female; Follicle | 1989 |
Lack of effect of spironolactone on hair shaft diameter in hirsute females.
Topics: Androgens; Canrenone; Double-Blind Method; Female; Gonadotropins, Pituitary; Hair; Hirsutism; Humans | 1989 |
Antiandrogens and hirsutism.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Androgen Antagonists; Clinical Trials as Topic; Cyproterone; Cy | 1987 |
Spironolactone in the treatment of hirsutism.
Topics: Adult; Androgens; Clinical Trials as Topic; Female; Hair; Hirsutism; Humans; Sex Hormone-Binding Glo | 1987 |
Endocrine and clinical effects of spironolactone in female hyperandrogenism.
Topics: Adult; Amenorrhea; Androgens; Double-Blind Method; Endocrine System Diseases; Female; Gonadotropins, | 1987 |
84 other studies available for spironolactone and Hirsutism
| Article | Year |
|---|---|
Spironolactone hyaluronic acid enriched cerosomes (HAECs) for topical management of hirsutism:
Topics: Administration, Topical; Androgen Antagonists; Animals; Ceramides; Chemistry, Pharmaceutical; Drug C | 2021 |
Female Pelvic Conditions: Polycystic Ovary Syndrome.
Topics: Acne Vulgaris; Anovulation; Female; Finasteride; Gonadotropin-Releasing Hormone; Hirsutism; Humans; | 2022 |
Long-Lasting Effects of Spironolactone after its Withdrawal in Patients with Hyperandrogenic Skin Disorders.
Topics: Female; Hirsutism; Humans; Neoplasm Recurrence, Local; Polycystic Ovary Syndrome; Quality of Life; R | 2023 |
[Impact of combined oral contraceptives and spironolactone on hirsutism and quality of life].
Topics: Contraceptives, Oral, Combined; Female; Hirsutism; Humans; Quality of Life; Retrospective Studies; S | 2022 |
High-dose spironolactone for acne in patients with polycystic ovarian syndrome: A single-institution retrospective study.
Topics: Acne Vulgaris; Female; Hirsutism; Humans; Mineralocorticoid Receptor Antagonists; Polycystic Ovary S | 2021 |
Spironolactone in Dermatology: Uses in Acne, Hidradenitis Suppurativa, Female Pattern Baldness, and Hirsutism.
Topics: Acne Vulgaris; Alopecia; Dermatology; Female; Hidradenitis Suppurativa; Hirsutism; Humans; Spironola | 2020 |
Spironolactone and breast cancer: Fear not!
Topics: Breast Neoplasms; Fear; Female; Hirsutism; Humans; Neoplasm Recurrence, Local; Retrospective Studies | 2020 |
Pharmaceutical and Pharmacological Evaluation of the Effect of Nano-Formulated Spironolactone and Progesterone on Inflammation and Hormonal Levels for Managing Hirsutism Experimentally Induced in Rats.
Topics: Animals; Drug Carriers; Drug Evaluation, Preclinical; Female; Hirsutism; Hydrogels; Inflammation; Na | 2021 |
Long-Term Response of Hirsutism and Other Hyperandrogenic Symptoms to Combination Therapy in Polycystic Ovary Syndrome.
Topics: Contraceptives, Oral; Cross-Sectional Studies; Drug Therapy, Combination; Female; Hirsutism; Humans; | 2018 |
Hirsutism - from diagnosis to use of antiandrogens.
Topics: Androgen Antagonists; Androstenes; Cyproterone Acetate; Female; Finasteride; Flutamide; Hirsutism; H | 2013 |
[Treatment of hirsutism].
Topics: Adult; Androgen Antagonists; Contraceptives, Oral, Combined; Diagnosis, Differential; Evidence-Based | 2009 |
Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism.
Topics: Adolescent; Adult; Child; Cholesterol, HDL; Cholesterol, LDL; Female; Hirsutism; Humans; Lipids; Min | 2009 |
Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis.
Topics: Adolescent; Adult; Androgen Antagonists; Female; Glucose Intolerance; Hirsutism; Humans; Hyperglycem | 2012 |
Aromatase gene polymorphism does not influence clinical phenotype and response to oral contraceptive pills in polycystic ovary syndrome women.
Topics: Adult; Androgens; Anovulation; Aromatase; Blood Pressure; Body Mass Index; Contraceptives, Oral; Eth | 2012 |
Pneumomediastinum after retching.
Topics: Adult; Female; Hirsutism; Humans; Mediastinal Emphysema; Mineralocorticoid Receptor Antagonists; Rad | 2012 |
From HAIR-AN to eternity.
Topics: Acanthosis Nigricans; Child; Female; Hirsutism; Humans; Hyperandrogenism; Insulin Resistance; Polycy | 2002 |
Comparison of spironolactone and spironolactone plus finasteride in the treatment of hirsutism.
Topics: Adult; Androgen Antagonists; Drug Therapy, Combination; Enzyme Inhibitors; Female; Finasteride; Hirs | 2002 |
The treatment of polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Cabergoline; Cardiovascular Diseases; Clomiphene; Cyproterone Acetate; | 2004 |
High serum prostate-specific antigen concentrations in hirsute women do not decrease with treatment by the combination of spironolactone and the contraceptive pill.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Biomarkers; Body Mass Index; Contraceptives, Oral; Dehydroepian | 2004 |
Assessment, diagnosis and treatment of a patient with hirsutism.
Topics: Adult; Androgen Antagonists; Cyproterone Acetate; Ethinyl Estradiol; Female; Hirsutism; Humans; Poly | 2008 |
[Indications and limits of anti-androgen therapy].
Topics: Acne Vulgaris; Alopecia; Androgen Antagonists; Chlormadinone Acetate; Cyproterone; Cyproterone Aceta | 1984 |
[Therapy of female hirsutism: current status and new findings].
Topics: Adrenal Cortex Hormones; Adrenal Hyperplasia, Congenital; Androgen Antagonists; Androgens; Bromocrip | 1983 |
[Cyproterone acetate and spironolactone compared in the therapy of female hirsutism].
Topics: Adolescent; Adult; Androgen Antagonists; Cyproterone; Cyproterone Acetate; Dihydrotestosterone; Drug | 1983 |
The influence of androgens on insulin resistance.
Topics: Adult; Androgens; Androstane-3,17-diol; Dehydroepiandrosterone; Dihydrotestosterone; Female; Hirsuti | 1984 |
[Hormonotherapy in acute, idiopathic hirsutism, and seborrheic alopecia (author's transl)].
Topics: Acne Vulgaris; Alopecia; Androgen Antagonists; Androgens; Cyproterone; Dermatitis, Seborrheic; Estro | 1982 |
Testosterone, 17 Ks, 17 beta E2 FSH-LH variations and hirsutism modifications during spironolactone therapy.
Topics: 17-Ketosteroids; Adolescent; Adult; Estradiol; Female; Follicle Stimulating Hormone; Hirsutism; Huma | 1984 |
[Spironolactone in idiopathic hirsutism, clinical and biological evaluation of treatment].
Topics: Adult; Female; Follicle Stimulating Hormone; Hirsutism; Humans; Luteinizing Hormone; Spironolactone; | 1983 |
[Diagnosis and treatment of hirsutism].
Topics: Androgen Antagonists; Cyproterone; Cyproterone Acetate; Dexamethasone; Drug Combinations; Ethinyl Es | 1984 |
[Long-term treatment of hirsutism with spirolactone].
Topics: Adult; Hirsutism; Humans; Male; Spironolactone | 1984 |
Induction of ovulation with spironolactone (Aldactone) in anovulatory oligomenorrheic and hyperandrogenic women.
Topics: 17-Ketosteroids; Androgens; Anovulation; Female; Follicle Stimulating Hormone; Hirsutism; Humans; Lu | 1981 |
Therapeutic effects of spironolactone in polycystic ovary syndrome.
Topics: Adult; Female; Hirsutism; Humans; Menstruation Disturbances; Pituitary Hormones; Polycystic Ovary Sy | 1983 |
Treatment of idiopathic hirsutism with spironolactone.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hirsutism; Humans; Middle | 1982 |
Hirsutism and problem of its management.
Topics: Adolescent; Adult; Allylestrenol; Dexamethasone; Ethinyl Estradiol; Female; Hirsutism; Humans; Polyc | 1982 |
[Results of treatment of hirsutism with spironolactone].
Topics: Adult; Androgen Antagonists; Female; Hirsutism; Humans; Luteinizing Hormone; Spironolactone; Testost | 1982 |
Treatment of hirsutism with spironolactone.
Topics: Amenorrhea; Androgen Antagonists; Androgens; Androstenedione; Cytochrome P-450 Enzyme Inhibitors; Fa | 1982 |
Successful treatment of polycystic ovary syndrome with spironolactone or bromocriptine.
Topics: Adult; Bromocriptine; Female; Hirsutism; Hormones; Humans; Hypertension; Polycystic Ovary Syndrome; | 1981 |
Clinical evaluation of the effects of combined treatment with bromocriptine and spironolactone in two women with the polycystic ovary syndrome.
Topics: Adult; Blood Pressure; Body Weight; Bromocriptine; Drug Therapy, Combination; Female; Glucose Tolera | 1981 |
Tumorigenic aspect of spironolactone.
Topics: Hirsutism; Humans; Neoplasms; Spironolactone | 1981 |
[Can the anti-androgenic effect of spironolactone contraindicate its use in pregnancy?].
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Animals; Female; Fetus; Genitalia, Male; Hirsutism; | 1980 |
A novel use of spironolactone: treatment of hirsutism.
Topics: Adolescent; Adult; Androgen Antagonists; Estradiol; Female; Hirsutism; Humans; Menstruation; Spirono | 1980 |
[Can the anti-androgenic effect of spironolactone contraindicate its use in pregnancy?].
Topics: Abnormalities, Drug-Induced; Androgen Antagonists; Androgens; Animals; Female; Fetus; Genitalia, Mal | 1980 |
Successful treatment of hirsutism in HAIR-AN syndrome using flutamide, spironolactone, and birth control therapy.
Topics: Acanthosis Nigricans; Adolescent; Androgen Antagonists; Contraceptives, Oral, Combined; Contraceptiv | 1997 |
Diane 35 and spironolactone combination in the treatment of hirsutism.
Topics: Androgen Antagonists; Cyproterone Acetate; Drug Combinations; Ethinyl Estradiol; Female; Hirsutism; | 2001 |
New therapeutic approach to the hirsute patient.
Topics: 17-Ketosteroids; Adolescent; Adult; Child; Female; Hair; Hirsutism; Humans; Receptors, Androgen; Spi | 1979 |
[Long-term minoxidil therapy: renin, aldosterone, noradrenaline and the need for beta blockers].
Topics: Adult; Aldosterone; Chlorthalidone; Female; Furosemide; Hirsutism; Humans; Hypertension; Male; Middl | 1978 |
Spironolactone therapy for hirsutism in a hyperandrogenic woman.
Topics: Adult; Androgens; Female; Hirsutism; Humans; Hypertension; Spironolactone | 1978 |
Spironolactone in dermatology.
Topics: Acne Vulgaris; Female; Hirsutism; Humans; Spironolactone | 1992 |
Antiandrogens in the treatment of acne and hirsutism.
Topics: Acne Vulgaris; Cyproterone; Hirsutism; Humans; Spironolactone | 1992 |
Therapeutic alternatives for the hirsute woman.
Topics: Adolescent; Adult; Androgen Antagonists; Cyproterone; Cyproterone Acetate; Drug Therapy, Combination | 1992 |
Predictors of clinical response in hirsute women treated with spironolactone.
Topics: Adolescent; Adult; Age Factors; Body Mass Index; Child; Contraceptives, Oral; Dehydroepiandrosterone | 1991 |
Peripheral androgen blockade versus glandular androgen suppression in the treatment of hirsutism.
Topics: Adolescent; Adult; Androgen Antagonists; Androgens; Androstane-3,17-diol; Androstenedione; Androster | 1991 |
Spironolactone for porphyria cutanea tarda associated hirsutism.
Topics: Adult; Female; Hirsutism; Humans; Porphyrias; Severity of Illness Index; Spironolactone | 1990 |
Treatment of androgenic disorders with dexamethasone: dose-response relationship for suppression of dehydroepiandrosterone sulfate.
Topics: Acne Vulgaris; Adolescent; Adult; Alopecia; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; | 1990 |
[Treatment of hirsutism with spironolactone and progestagen combination].
Topics: Acne Vulgaris; Adolescent; Adult; Drug Therapy, Combination; Female; Hirsutism; Humans; Norprogester | 1990 |
Use of spironolactone in treatment of hirsutism.
Topics: Contraceptives, Oral; Dexamethasone; Drug Therapy, Combination; Female; Hirsutism; Humans; Spironola | 1990 |
Hirsutism in a gynaecological context.
Topics: Adult; Anovulation; Contraceptives, Oral, Hormonal; Female; Gonadal Steroid Hormones; Hirsutism; Hum | 1990 |
Hirsutism--a low dose spironolactone therapy.
Topics: Adolescent; Adult; Female; Follicle Stimulating Hormone; Hirsutism; Humans; Luteinizing Hormone; Spi | 1989 |
Spironolactone is an effective and well tolerated systemic antiandrogen therapy for Hirsute women.
Topics: Adult; Androgen Antagonists; Drug Tolerance; Female; Hair; Hirsutism; Humans; Menstrual Cycle; Spiro | 1989 |
Absence of progestational activity of oral spironolactone.
Topics: Endometrium; Estrogens; Female; Hirsutism; Humans; Menstruation Disturbances; Progesterone; Prolacti | 1989 |
The treatment of hirsutism: experience with cyproterone acetate and spironolactone.
Topics: Androgen Antagonists; Cyproterone; Cyproterone Acetate; Female; Hirsutism; Humans; Spironolactone; T | 1985 |
[State of the hypothalamo-hypophyseo-ovarian function in patients with hyperandrogenemia during treatment with spironolactone].
Topics: Adult; Female; Hirsutism; Humans; Hypothalamo-Hypophyseal System; Ovary; Spironolactone; Testosteron | 1985 |
[The concept of the causal therapy of hirsutism].
Topics: Cimetidine; Cyproterone; Cyproterone Acetate; Hirsutism; Humans; Medroxyprogesterone; Medroxyprogest | 1986 |
The endocrine effects of spironolactone used as an antiandrogen.
Topics: Adult; Androstenedione; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Dexamethasone; Femal | 1987 |
Tolerance of spironolactone.
Topics: Acne Vulgaris; Adult; Androgen Antagonists; Contraceptives, Oral; Drug Tolerance; Female; Hirsutism; | 1988 |
The effects of spironolactone on adrenal steroidogenesis in hirsute women.
Topics: 17-alpha-Hydroxyprogesterone; Adrenal Glands; Adrenocorticotropic Hormone; Adult; Androgens; Androst | 1985 |
Spironolactone in the treatment of hirsutism.
Topics: 17-Ketosteroids; Adolescent; Adult; Female; Follicle Stimulating Hormone; Hirsutism; Humans; Spirono | 1987 |
Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia.
Topics: Acne Vulgaris; Alopecia; Androgen Antagonists; Female; Hirsutism; Humans; Spironolactone | 1985 |
Spironolactone in combination drug therapy for unresponsive hirsutism.
Topics: Contraceptives, Oral; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Dexamethasone; Drug Th | 1985 |
Side-effects of spironolactone therapy in the hirsute woman.
Topics: Adult; Alopecia; Female; Hirsutism; Humans; Menstrual Cycle; Metrorrhagia; Spironolactone; Testoster | 1988 |
Spironolactone and estrogen-progestin therapy for hirsutism.
Topics: Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Ethinyl Estradiol; Female; | 1987 |
Drug therapy for hirsutism.
Topics: Androgen Antagonists; Cyproterone; Estrogens; Female; Glucocorticoids; Hirsutism; Humans; Spironolac | 1987 |
A comparative study of Aldactone and Diane in the treatment of hirsutism.
Topics: Adolescent; Adult; Cyproterone; Cyproterone Acetate; Drug Combinations; Drug Evaluation; Ethinyl Est | 1987 |
Clinical usefulness of plasma androstanediol glucuronide measurements in women with idiopathic hirsutism.
Topics: Adolescent; Adult; Androstane-3,17-diol; Androstanols; Contraceptives, Oral, Combined; Contraceptive | 1987 |
Prolonged suppression of hirsutism with combination therapy in an adolescent with insulin resistance and acanthosis nigricans.
Topics: Acanthosis Nigricans; Adolescent; Drug Therapy, Combination; Ethinyl Estradiol; Female; Hirsutism; H | 1987 |
Spironolactone in the treatment of hirsutism.
Topics: Female; Gonadal Steroid Hormones; Gonadotropins, Pituitary; Hirsutism; Humans; Spironolactone | 1986 |
Spironolactone in the treatment of idiopathic hirsutism and the polycystic ovary syndrome.
Topics: Adolescent; Adult; Female; Hirsutism; Humans; Menstruation Disturbances; Middle Aged; Polycystic Ova | 1986 |
Therapeutic evaluation of spironolactone in Indian women with hirsutism.
Topics: Adolescent; Adult; Drug Therapy, Combination; Ethinyl Estradiol; Ethinyl Estradiol-Norgestrel Combin | 1986 |
Spironolactone in combination with an oral contraceptive: an alternative treatment for hirsutism.
Topics: Contraceptives, Oral, Hormonal; Drug Therapy, Combination; Female; Hirsutism; Humans; Spironolactone | 1986 |
The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women.
Topics: Adult; Androgen Antagonists; Androgens; Dose-Response Relationship, Drug; Female; Hair; Hirsutism; H | 1985 |
Treatment of hirsutism with spironolactone.
Topics: Androgens; Drug Administration Schedule; Female; Hirsutism; Humans; Menstruation Disturbances; Spiro | 1985 |
The effect of spironolactone on genital skin 5 alpha-reductase activity.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Adult; Female; Hirsutism; Humans; Kinetics; Oxidoreductases; | 1985 |
Bioavailability of albumin-bound testosterone.
Topics: Adult; Biological Availability; Brain; Carotid Arteries; Computers; Female; Hirsutism; Humans; Injec | 1985 |
Spironolactone in combination with an oral contraceptive: an alternative treatment for hirsutism.
Topics: Contraceptives, Oral, Combined; Contraceptives, Oral, Hormonal; Drug Combinations; Drug Therapy, Com | 1985 |
The effect of spironolactone on hirsutism and female androgen metabolism.
Topics: Adolescent; Adult; Androgen Antagonists; Female; Hair; Hirsutism; Humans; Spironolactone; Testostero | 1985 |